The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis

European Respiratory Journal

Volumn 14, Issue 3, 1999, Pages 693-696

  Rodgers, H C ^a   Knox, A J ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Amiloride; Benzamil; Cystic fibrosis; Nasal potential difference

Indexed keywords

AMILORIDE; BENZAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHUS MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TRANSPORT; HUMAN; LUNG FIBROSIS; NOSE MUCOSA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM ABSORPTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AMILORIDE; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; ELECTRIC IMPEDANCE; HUMANS; MEMBRANE POTENTIALS; NASAL MUCOSA; RETROSPECTIVE STUDIES; SODIUM CHANNEL BLOCKERS;

EID: 0032833866     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.14c32.x     Document Type: Article

References (28)

1. Knowles MR, Gatzy JT, Boucher RC. Increased biolectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981; 305 (25): 1489-1495.
2. Boucher RC, Stutts MJ, Knowles MR. Na transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986; 78: 1245-1252.
3. Boucher RC, Cotton CU, Gatzy JT. Evidence for reduced Cl and increased Na permeability in cystic fibrosis human primary cell cultures. J Physiol 1988; 405: 77-103.
4. Knowles MR, Carson JL, Collier AM, Gatzy JT, Boucher RC. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo. Am Rev Respir Dis 1981; 124: 484-490.
5. Alton EWFW, Currie D, Logan Sinclair R, Warner J, Hodson ME, Geddes DM. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990; 3: 922-926.
6. Middleton PG, Geddes DM, Alton EWFW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994; 7: 2050-2056.
7. Peckham DG, Conn A, Chotai C, Lewis S, Knox AJ. Effect of oral digoxin, topical oubain and salbutamol on trans-epithelial nasal potential difference in patients with cystic fibrosis. Clin Science 1995; 89: 277-284.
8. Simchowitz L, Kleyman TR, Cragoe EJ. An overview of the structure - activity relations in the amiloride series. In: Cragoe EJ, Kleyman T, Simchowitz L, eds. Amiloride and its analogs - Unique cation transport inhibitors, New York VCH; 1992: 9-24.
9. Young S, Benos O, Benos DJ. Amiloride-Sensitive Sodium Channels. In: Cragoe EJ, Kleyman TR, Simcchowitz L, eds. Amiloride and its Analogs. Unique cation transport inhibitors, New York, VCH, 1992; 41-56.
10. Bowler IM, Kelman B, Worthington D, et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995; 73: 427-430.
11. Knowles MR, Church NL, Waltner WE, Yankakas JR, Gilligan P. A Pilot Study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189-1194.
12. Graham A, Hasani A, Alton EWFW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-1248.
13. Mentz WM, Brown JB, Friedman M, Stutts MJ, Gatzy JT, Boucher RC. Deposition, clearance and effects of aerosolized amiloride in sheep airways. Am Rev Respir Dis 1986; 134: 938-943.
14. Middleton PG, Geddes DM, Alton EWFW. Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects. Thorax 1993; 48: 812-816.
15. App EM, King M, Helfesrieder R, Kohler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis 1990; 141: 605-612.
16. Knowles MR, Church NL, Waltner WE, Gatzy JT, Boucher RC. Amiloride in cystic fibrosis: safety, pharmacokinetics, and efficacy in the treatment of pulmonary disease. In: Cragoe EJ, Kleyman TR, Simchowitz L, eds. Amiloride and its Analogs - Unique Cation Transport Inhibitors. New York, VCH, 1992; 301-316.
17. Blank U, Clauss W, Weber WM. Effects of benzamil on human cystic fibrosis airway epithelium. Cell Physiol Biochem 1995; 5: 385-390.
18. Hodmann T, Stutts MT, Ziersch A, et al. Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 1844-1849.
19. Middleton PG, Caplen NJ, Gao X, et al. Nasal application of cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J 1994; 7: 442-445.
20. Waltner WE, Church NL, Gatzy JT, Boucher RC, Knowles MR. Deposition, pharmacokinetics and toxicity of amiloride aerosol in normal and cystic fibrosis subjects. Am Rev Respir Dis 1987; 135: A288.
21. Hoffman T, Boy CE, Robinson JM, Homely V, Butcher RC, Knolls MR. Dexamethasone increases sodium transport in human nasal epithelium in vivo. Pediatr Pulmonol 1997; 14: 234.
22. Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-831.
23. Caplen NJ, Alton EWFW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995; 1: 39-46.
24. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325: 533-538.
25. Knowles MR, Clarke LL, Boucher RC. Extracellular ATP and UTP induce chloride secretion in nasal epithelia of cystic fibrosis patients and normal subjects in vivo. Chest 1992; 101 (3): 60S-63S.
26. Eidelman O, Guay-Broder C, Van Galen PJM, et al. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Pro Natl Acad Sci 1991; 89: 5562-5566.
27. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4 Phenylbutyrate (Buphenyl) in delta F508 -Homozygous cystic fibrosis patients. Am J Respir Crit Care Med 1998; 157: 484-490.
28. Cheng SH, Fang SL, Zabner J, et al. Functional activation of the cystic fibrosis trafficking mutant Delta F508-CFTR by overexpression. Am J Physiol 1995; 268: L615-L624.